AP Biosciences, Inc. (TPEX:6945)
Taiwan
· Delayed Price · Currency is TWD 186.50
0.00 (0.00%)
Apr 29, 2026, 2:00 PM CST
AP Biosciences Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | -444.77 | -422.75 | -339.3 | -288.54 | -187.61 | Upgrade
|
| Depreciation & Amortization | 25.47 | 17.33 | 11.6 | 7.42 | 8.39 | Upgrade
|
| Other Amortization | 0.04 | 0.16 | 0.98 | 1.25 | 0.47 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 1.23 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 75.13 | 55.69 | 24.74 | 29 | 2.94 | Upgrade
|
| Other Operating Activities | 3.23 | -2.92 | 0.79 | -0.89 | - | Upgrade
|
| Change in Accounts Receivable | -3.39 | 0.75 | -2.31 | -0.12 | 0.09 | Upgrade
|
| Change in Accounts Payable | 1.31 | 5.78 | 14.58 | -16.59 | 12.39 | Upgrade
|
| Change in Other Net Operating Assets | -10.35 | -11.91 | -8.7 | -7.51 | -5.36 | Upgrade
|
| Operating Cash Flow | -352.09 | -357.88 | -297.62 | -275.97 | -168.68 | Upgrade
|
| Capital Expenditures | -25.03 | -5.53 | -35.03 | -1.13 | -3.9 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.23 | - | -0.38 | -1.31 | -1.02 | Upgrade
|
| Investment in Securities | -100 | 331.9 | -430.7 | -0.71 | -30 | Upgrade
|
| Other Investing Activities | 0.01 | 0 | -2.56 | -0 | -0.01 | Upgrade
|
| Investing Cash Flow | -125.25 | 326.37 | -468.68 | -3.15 | -34.92 | Upgrade
|
| Long-Term Debt Repaid | -11.4 | -11.17 | -3.11 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -11.4 | -11.17 | -3.11 | - | - | Upgrade
|
| Issuance of Common Stock | 15.91 | 1,207 | - | 800 | 100 | Upgrade
|
| Financing Cash Flow | 4.51 | 1,196 | -3.11 | 800 | 100 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.08 | -1.08 | - | - | - | Upgrade
|
| Net Cash Flow | -470.75 | 1,163 | -769.4 | 520.88 | -103.6 | Upgrade
|
| Free Cash Flow | -377.12 | -363.41 | -332.65 | -277.1 | -172.58 | Upgrade
|
| Free Cash Flow Margin | - | - | -1031.37% | - | -2467.90% | Upgrade
|
| Free Cash Flow Per Share | -4.43 | -4.83 | -5.14 | -5.26 | -7.16 | Upgrade
|
| Cash Interest Paid | 1.31 | 1.54 | 1.13 | - | - | Upgrade
|
| Levered Free Cash Flow | -220.5 | -213.19 | -211.61 | -175.83 | -103.12 | Upgrade
|
| Unlevered Free Cash Flow | -219.61 | -212.16 | -210.86 | -175.83 | -103.12 | Upgrade
|
| Change in Working Capital | -12.42 | -5.38 | 3.57 | -24.22 | 7.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.